Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 10, Issue 3, 2009, Pages 157-167

  Andersen, Karl ^a   Weinberger, Myron H ^b   Constance, Christian M ^c   Ali, Mohammed A ^d   Jin, James ^d   Prescott, Margaret F ^d   Keefe, Deborah L ^d  

^a UNIVERSITY OF ICELAND   (Iceland)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ACE inhibitor; Aliskiren; Direct renin inhibitor; Diuretic; Hydrochlorothiazide; Hypertension; Ramipril; Renin

Indexed keywords

ALDOSTERONE; ALISKIREN; C REACTIVE PROTEIN; HYDROCHLOROTHIAZIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RAMIPRIL; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ALBUMINURIA; AMIDES; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CREATININE; DEMOGRAPHY; DIASTOLE; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RAMIPRIL; RENIN; RENIN-ANGIOTENSIN SYSTEM; SYSTOLE; TIME FACTORS;

EID: 69849112971     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320309342407     Document Type: Article

References (35)

1. Vander AJ, Geelhoed GW Inhibition of renin secretion by angiotensin. II. Proc Soc Exp Biol Med 1965;120:399-403.
2. Azizi M., Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004;109:2492-9.
3. Hollenberg NK, Fisher ND, Price DA Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.
4. Mooser V., Nussberger J., Juillerat L. et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990;15:276-82.
5. van den Meiracker AH, Jan Danser AH Aliskiren: The first direct renin inhibitor for hypertension. Curr Cardiol Rep 2007;9:470-6.
6. Oh BH, Mitchell J., Herron JR et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63.
7. Villamil A., Chrysant SG, Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26.
8. Pool JL, Gradman AH, Kolloch R. et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J 2006;27(suppl):119.
9. Azizi M., Menard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126-33.
10. Oparil S., Yarows SA, Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007;370:221-9.
11. Jordan J., Engeli S., Boye SW et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047-55.
12. Gradman AH, Flack JM, Arora V. et al. Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: A pooled analysis of 1612 patients with hypertension. Circulation 2006;114(suppl 18):773.
13. Uresin Y., Taylor AA, Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8.
14. Latini R., Masson S., Anand I. et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9.
15. Vergaro G., Fontana M., Poletti R. et al. Plasma renin activity is an independent prognostic factor in chronic heart failure. Eur Heart J 2008;29(suppl 1):393.
16. Azizi M. Renin inhibition. Curr Opin Nephrol Hypertens 2006;15:505-10.
17. Andersen K., Weinberger MH, Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-99.
18. Yusuf S., Sleight P., Pogue J. et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
19. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-18.
20. Lees KR The dose-response relationship with angiotensin converting enzyme inhibitors: Effects on blood pressure and biochemical parameters. J Hypertens 1992;10(suppl):S3-11.
21. de Leeuw PW, Lugtenburg PL, van Houten H. et al. Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients. J Cardiovasc Pharmacol 1985;7:1161-5.
22. Menard J., Guyene TT, Peyrard S., Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens 2006;24:529-34.
23. Nussberger J., Gradman AH, Schmieder RE et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007;61:1461-8.
24. Menard J., Azizi M. The difficult conception, birth and delivery of a renin inhibitor: Controversies around aliskiren. J Hypertens 2007;25:1775-82.
25. Danser AH, Charney A., Feldman DL et al. The renin rise with aliskiren: it's simply stoichiometry. Hypertension 2008;51:e27-8.
26. Feldman DL, Jin L., Xuan H. et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;52:130-6.
27. Krop M., Garrelds IM, de Bruin RJ et al. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008;52:1076-83.
28. Sealey JE, Laragh JH Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness. Am J Hypertens 2007;20:587-97.
29. Alderman MH, Cohen HW, Sealey JE, Laragh JH Plasma renin activity levels in hypertensive persons: Their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004;17:1-7.
30. Koulouris S., Symeonides P., Triantafyllou K. et al. Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus. Am J Cardiol 2005;95:1386-8.
31. Mitrovic V., Klein HH, Krekel N. et al. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol 2005;94:336-42.
32. Lopez Santi RG, Valeff EC, Duymovich CR et al. Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study. Coron Artery Dis 2005;16:423-9.
33. Ridker PM, Danielson E., Rifai N., Glynn RJ Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension 2006;48:73-9.
34. Parving HH, Persson F., Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46.
35. Persson F., Rossing P., Schjoedt KJ et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008;73:1419-25.